Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityNon-Current AssetsOther Accumulated ExpensesOther Non-Current AssetsPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Retained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Whitehawk Therapeutics (WHWK) Cash & Current Investments (2018 - 2025)

Whitehawk Therapeutics (WHWK) has disclosed Cash & Current Investments for 8 consecutive years, with $253.8 million as the latest value for Q4 2025.

  • Quarterly Cash & Current Investments rose 437.35% to $253.8 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $253.8 million through Dec 2025, up 437.35% year-over-year, with the annual reading at $253.8 million for FY2025, 437.35% up from the prior year.
  • Cash & Current Investments for Q4 2025 was $253.8 million at Whitehawk Therapeutics, up from $162.6 million in the prior quarter.
  • The five-year high for Cash & Current Investments was $253.8 million in Q4 2025, with the low at $36.8 million in Q2 2021.
  • Average Cash & Current Investments over 5 years is $131.9 million, with a median of $132.3 million recorded in 2022.
  • The sharpest move saw Cash & Current Investments tumbled 56.6% in 2024, then skyrocketed 437.35% in 2025.
  • Over 5 years, Cash & Current Investments stood at $149.0 million in 2021, then grew by 15.82% to $172.6 million in 2022, then crashed by 36.92% to $108.8 million in 2023, then crashed by 56.6% to $47.2 million in 2024, then surged by 437.35% to $253.8 million in 2025.
  • According to Business Quant data, Cash & Current Investments over the past three periods came in at $253.8 million, $162.6 million, and $209.5 million for Q4 2025, Q3 2025, and Q2 2025 respectively.